Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mien Sho

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Experimental and Molecular Pathology|March 14, 2002
Subnormal shear stress-induced intimal thickening requires medial smooth muscle cell proliferation and migrationMien Sho, Eiketsu Sho, Tej M Singh, et al.
Journal of Vascular Surgery|August 4, 2010
Hyperglycemia limits experimental aortic aneurysm progressionNoriyuki Miyama, Monica M Dua, Janice J Yeung, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 17, 2002
Flow loading induces macrophage antioxidative gene expression in experimental aneurysmsTakeshi K Nakahashi, Katsuyuki Hoshina, Philip S Tsao, et al.
Journal of Immunology Research|October 28, 2017
Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector CellsShiming Ye, Melvin I Fox, Nicole A Belmar, et al.
Frontiers in Immunology|January 11, 2014
Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakRJames W Purcell, Han K Kim, Sonia G Tanlimco, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 4, 2009
Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progressionMaureen M Tedesco, Masahiro Terashima, Francis G Blankenberg, et al.
Journal of Cancer Research and Clinical Oncology|October 18, 2012
Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAbDebra T Chao, Mian Su, Sonia Tanlimco, et al.
Molecular Cancer Therapeutics|January 25, 2020
Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver ToxicitySun K Ho, Zhenghai Xu, Archana Thakur, et al.
Cancer Immunology Research|August 30, 2019
A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific ImmunityShiming Ye, Diane Cohen, Nicole A Belmar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanismsPatricia A Culp, Donghee Choi, Yongke Zhang, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Experimental and Molecular Pathology|March 14, 2002
Subnormal shear stress-induced intimal thickening requires medial smooth muscle cell proliferation and migrationMien Sho, Eiketsu Sho, Tej M Singh, et al.
Journal of Vascular Surgery|August 4, 2010
Hyperglycemia limits experimental aortic aneurysm progressionNoriyuki Miyama, Monica M Dua, Janice J Yeung, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 17, 2002
Flow loading induces macrophage antioxidative gene expression in experimental aneurysmsTakeshi K Nakahashi, Katsuyuki Hoshina, Philip S Tsao, et al.
Journal of Immunology Research|October 28, 2017
Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector CellsShiming Ye, Melvin I Fox, Nicole A Belmar, et al.
Frontiers in Immunology|January 11, 2014
Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakRJames W Purcell, Han K Kim, Sonia G Tanlimco, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 4, 2009
Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progressionMaureen M Tedesco, Masahiro Terashima, Francis G Blankenberg, et al.
Journal of Cancer Research and Clinical Oncology|October 18, 2012
Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAbDebra T Chao, Mian Su, Sonia Tanlimco, et al.
Molecular Cancer Therapeutics|January 25, 2020
Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver ToxicitySun K Ho, Zhenghai Xu, Archana Thakur, et al.
Cancer Immunology Research|August 30, 2019
A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific ImmunityShiming Ye, Diane Cohen, Nicole A Belmar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanismsPatricia A Culp, Donghee Choi, Yongke Zhang, et al.
Pageof 3